These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24697778)

  • 1. Sample size consideration for immunoassay screening cut-point determination.
    Zhang J; Zhang L; Yang H
    J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods and tool for cut point analysis in immunogenicity assays.
    Zhang L; Zhang JJ; Kubiak RJ; Yang H
    J Immunol Methods; 2013 Mar; 389(1-2):79-87. PubMed ID: 23305975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
    Wadhwa M; Gaines-Das R; Thorpe R; Mire-Sluis A
    Dev Biol (Basel); 2005; 122():155-70. PubMed ID: 16375260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity/hypersensitivity of biologics.
    Leach MW; Rottman JB; Hock MB; Finco D; Rojko JL; Beyer JC
    Toxicol Pathol; 2014 Jan; 42(1):293-300. PubMed ID: 24240973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
    Wadhwa M; Bird C; Dilger P; Gaines-Das R; Thorpe R
    J Immunol Methods; 2003 Jul; 278(1-2):1-17. PubMed ID: 12957392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.
    Goodman J; Cowen S; Devanarayan V; Egging D; Emrich T; Golob M; Kramer D; McNally J; Munday J; Nelson R; Pedras-Vasconcelos JA; Piironen T; Sickert D; Skibeli V; Fjording MS; Timmerman P
    Bioanalysis; 2018 Feb; 10(4):197-204. PubMed ID: 29345496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
    Koren E; Smith HW; Shores E; Shankar G; Finco-Kent D; Rup B; Barrett YC; Devanarayan V; Gorovits B; Gupta S; Parish T; Quarmby V; Moxness M; Swanson SJ; Taniguchi G; Zuckerman LA; Stebbins CC; Mire-Sluis A
    J Immunol Methods; 2008 Apr; 333(1-2):1-9. PubMed ID: 18275969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidrug antibody assay validation: industry survey results.
    Gorovits B
    AAPS J; 2009 Mar; 11(1):133-8. PubMed ID: 19255857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut-Point Suitability Across Tumor Types.
    Valentine JL; Dengler A; Zhao A; Truong T; McAfee S; Hassanein M; Irvin SC; Chen J; Meng X; Yan H; Torri A; Sumner G; Andisik MD; Paccaly A; Partridge MA
    J Clin Pharmacol; 2024 Jan; 64(1):125-136. PubMed ID: 37656820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.